A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia
ID Number 15-2243Principal Investigator(s)
Department(s) or Division(s)
Hematology and Medical Oncology
The purpose of this study, which involves research, is to determine if an experimental drug: ACP-196 is safe and effective in the treatment of this disease.
ACP-196 is an investigational drug. An experimental drug is not approved by the United States Food and Drug Administration (FDA) for use except in research studies. ACP-196 has been tested previously in approximately 242 humans and has been well tolerated. ACP-196 is administered as an oral capsule.
Recruiting Patients: Yes